NCX 667

NCX 667 is a novel nitric oxide (NO) donor small molecule characterized by a di-nitrooxy ester moiety anchored on an isomannide core. It is being developed as an intraocular pressure (IOP)-lowering agent for the treatment of ocular hypertension and glaucoma. The drug lowers IOP in normotensive and hypertensive animal models, with a rapid and potent effect following topical administration. Its primary mechanism involves NO-mediated stimulation of the soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway, which increases conventional outflow facility via relaxation of the trabecular meshwork and Schlemm’s canal tissues. Preclinical studies indicate NCX 667 is well tolerated without signs of tachyphylaxis or ocular discomfort, and does not cause significant changes to cAMP or other off-target effects in ocular tissues. Currently, NCX 667 is not yet approved and remains in preclinical or early clinical development for glaucoma and ocular hypertension[1][5][4][6].